Provided by Tiger Fintech (Singapore) Pte. Ltd.

WAVE Life Sciences

6.97
-0.1900-2.65%
Post-market: 6.87-0.1000-1.43%19:39 EDT
Volume:1.85M
Turnover:13.02M
Market Cap:1.11B
PE:-8.33
High:7.18
Open:7.15
Low:6.95
Close:7.16
52wk High:16.74
52wk Low:5.28
Shares:159.14M
Float Shares:65.41M
Volume Ratio:0.80
T/O Rate:2.83%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8368
EPS(LYR):-0.7015
ROE:-171.41%
ROA:-38.90%
PB:7.96
PE(LYR):-9.94

Loading ...

Stock Track | WAVE Life Sciences Surges 8.92% Pre-market on Canaccord's Buy Rating and $19 Price Target

Stock Track
·
Aug 04

Stock Track | WAVE Life Sciences Soars 8.92% Pre-market on Bullish Analyst Coverage

Stock Track
·
Aug 04

Canaccord Genuity Initiates Wave Life Sciences at Buy With $19 Price Target

MT Newswires Live
·
Aug 04

Stock Track | WAVE Life Sciences Plummets 5.05% as Q2 Results Miss Estimates, Revenue Drops 56%

Stock Track
·
Jul 30

Stock Track | Wave Life Sciences Plummets 5.05% After Q2 Earnings Miss and Revenue Decline

Stock Track
·
Jul 30

Earnings Flash (WVE) Wave Life Sciences Posts Q2 Net Loss $0.31 a Share, vs. FactSet Est of $0.28 Loss

MT Newswires Live
·
Jul 30

WAVE Life Sciences Q2 EPS $(0.31) Misses $(0.29) Estimate, Sales $8.699M Miss $11.245M Estimate

Benzinga
·
Jul 30

Wave Life Sciences Reports Q2 2025 Revenue Drop to $8.7M and Net Loss Increase to $50.5M

Reuters
·
Jul 30

Wave Life Sciences Q2 Revenue USD 8.699 Million VS. Ibes Estimate USD 10.4 Million

THOMSON REUTERS
·
Jul 30

Wave Life Sciences Q2 Income From Operations USD -52.759 Million VS. Ibes Estimate USD -49.8 Million

THOMSON REUTERS
·
Jul 30

Oppenheimer Initiates Coverage on Wave Life Sciences With Outperform Rating, $24 Price Target

MT Newswires Live
·
Jul 28

Wave Life Sciences Ltd. to Release Second Quarter 2025 Financial Results

Reuters
·
Jul 23

Citigroup Initiates Wave Life Sciences at Buy With $16 Price Target

MT Newswires Live
·
Jul 16

Wave Life Sciences Initiated at Buy by Citigroup

Dow Jones
·
Jul 16

Wave Life Sciences Price Target Maintained With a $18.00/Share by Wedbush

Dow Jones
·
Jun 23

Wave Life Sciences Announces Promising Preclinical Results for WVE-007, Aiming to Revolutionize Obesity Treatment with Novel RNA Medicine

Reuters
·
Jun 21

Gregory L. Verdine, Director, Reports Disposal of Common Shares of Wave Life Sciences Ltd

Reuters
·
Jun 14

Wave Life Sciences Ltd. to Participate in Analyst-Led Fireside Chat at 2025 Jefferies Global Healthcare Conference

Reuters
·
May 29

Wave Life Sciences Appoints Dr. Christopher Wright as Chief Medical Officer to Lead RNA Medicines Development

Reuters
·
May 28

RBC Cuts Price Target on Wave Life Sciences to $9 From $10, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
May 09